Takeda-Shire In India: Sleeping Giant?
Will Takeda take a less measured approach in India, where Shire brings it a significant on-market portfolio? Scrip outlines the current shape of things in the promising but complex emerging market as the two companies head towards combining forces globally.
You may also be interested in...
Takeda Expands Hemophilia Play In India But Hemlibra Has Made Inroads
Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary
Takeda Brings Rare Disease Drugs To India But Access Questions Linger
Takeda has introduced rare disease therapies from Shire’s portfolio in India and appears to be shifting gears in a market where it has long adopted a measured approach. But pricing and access to these products pose challenges that the Japanese multinational will need to address.
Takeda Executive Rejig In ICMEA Region As Shire Integration Shapes
Takeda has shuffled certain key executive positions in the ICMEA (India, CIS, the Middle East and Africa) region where it hopes to sharpen its focus, while also emerging more agile as the integration with Shire advances.